Literature DB >> 22748538

Clinicopathologic and survival differences between upper and lower extremity melanomas.

Michael E Egger1, Brittany L Tabler, Erik M Dunki-Jacobs, Glenda G Callender, Charles R Scoggins, Robert C G Martin, Amy R Quillo, Arnold J Stromberg, Kelly M McMasters.   

Abstract

This analysis was performed to compare differences in clinicopathologic factors, sentinel lymph node (SLN) status, and survival between upper extremity (UE) and lower extremity (LE) melanoma patients. Post hoc analysis of a prospective clinical trial was performed of all patients with extremity melanomas with complete data. Survival was evaluated with Kaplan-Meier analysis. Univariate and multivariate analyses were performed. A total of 1115 patients aged 18 to 70 years with extremity melanomas ≥ 1.0 mm Breslow thickness were analyzed; all underwent SLN biopsy with completion lymphadenectomy for a tumor-positive SLN. Compared with UE patients, LE melanoma patients were younger, predominantly female, and had a higher rate of SLN metastasis. Kaplan-Meier analysis revealed worse 5-year disease-free survival (DFS) and worse local and in-transit recurrence-free survival in LE versus UE melanoma patients, but no difference in overall survival (OS). Subgroup analysis revealed that older patients (age > 51 years) with LE melanomas had worse DFS, local and in-transit recurrence-free-survival, and OS. LE tumor location was not an independent risk factor for OS or DFS. Compared with UE melanoma patients, those with LE melanomas have a greater risk of tumor-positive SLN and local/in-transit recurrence.

Entities:  

Mesh:

Year:  2012        PMID: 22748538

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  4 in total

1.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

Review 2.  The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.

Authors:  Emmanuel Gabriel; Joseph Skitzki
Journal:  Cancers (Basel)       Date:  2015-07-01       Impact factor: 6.639

3.  Dermoscopic and clinical features of head and neck melanoma.

Authors:  Fatma Pelin Cengiz; Abdurrahman Bugra Cengiz; Nazan Emiroglu; Ela Comert; Rainer Hofmann Wellenhof
Journal:  An Bras Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.896

4.  The Importance of Dermoscopy in Early Recognition of Melanoma in Situ.

Authors:  S L Ianosi; M X Calbureanu-Popescu; N G Ianosi; C V Tutunaru; C D Neagoe
Journal:  Curr Health Sci J       Date:  2019-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.